PanoramicaGraficoProfiloStatistiche chiaveDati finanziariNotizieSchermataTrader

OPKO Health/  US68375N1037  /

IEX
08/11/2024  21:59:55 Var. +0.07 Volume Denaro- Lettera- Max Min
1.51USD +4.86% 169,226
Fatturato: 255,909.38		 -Quantità in denaro: - -Quantità in lettera: - 1.55 1.45
GlobeNewswire 20/08 Entera Bio to Participate in Upcoming Investor and Scientific Conferences
GlobeNewswire 09/08 Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
GlobeNewswire 07/08 OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results
GlobeNewswire 01/08 OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024
GlobeNewswire 01/08 Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women w...
GlobeNewswire 18/07 OPKO Health Announces $100 Million Share Repurchase Program
GlobeNewswire 17/07 OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA...
GlobeNewswire 03/06 Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612)...
GlobeNewswire 31/05 OPKO Health to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire 15/05 Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire 13/05 Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Tr...
GlobeNewswire 10/05 Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
GlobeNewswire 07/05 OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
GlobeNewswire 03/05 OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
GlobeNewswire 08/04 Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the...
GlobeNewswire 26/03 Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FD...
GlobeNewswire 20/03 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire 08/03 Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
GlobeNewswire 05/03 AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the ...
GlobeNewswire 04/03 Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire 28/02 AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors
GlobeNewswire 27/02 OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
GlobeNewswire 22/02 OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
GlobeNewswire 02/02 SAB Biotherapeutics Announces Executive Leadership Change
GlobeNewswire 30/01 Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference